Global Healthcare

Pharmacovigilance Market Share, Company Analysis and Forecast 2019-2026

Press release   •   Sep 17, 2019 15:37 BST

The global pharmacovigilance market size is expected to reach USD 11.78 billion by 2026 and it is projected to expand at a CAGR of 13.3% during the forecast period 2019 to 2026.

Increasing incidence of Adverse Drug Reactions (ADR) is the key growth driver. The U.S. Food and Drug Administration (FDA) received approximately 253,017 serious adverse events and 44,693 deaths associated with ADRs in 2015. This shows the potential demand for implementing safety and Pharmacovigilance (PV) services.

Increasing acceptance and adoption of outsourcing services by healthcare companies will stimulate pharmacovigilance (PV) market growth in forthcoming years. Outsourcing eliminates the risk of business overhead costs as well as deployment of a pharmacovigilance resources. Outsourcing strategy increases the cost-effectiveness and efficiency by relieving resource pressure on firms. Positively shifting trends in PV outsourcing owing to increasing benefits will accelerate pharmacovigilance business growth in the coming years.

Get Free Report Sample Copy for More Understanding@ https://www.visionresearchreports.com/report/sample/28880

Rising number of adverse drug reactions (ADRs) will contribute to significant increase in the market size over the forecast period. According to National Centre for Biotechnology Information (NCBI), number of fatalities due to ADRs increased more than two-fold in 2014. This further led to increase in hospitalizations. Similarly, according to data by Clinics, 2018, there was 10.3% increase in ADR rate in Brazil per medication introduced during hospitalization. Such escalating number of ADRs that require continuous pharmacovigilance will render lucrative growth opportunity for pharmacovigilance market to facilitate effective surveillance of ADRs.

Accelerating demand for personalized medicines will impel momentous industry growth in the foreseeable future. Innovations in personalized medicine will offer growth potential to the market in ways to develop and quantitate risks and benefits of personalized medicines. Increasing advancement in targeted drugs such as new product development will further propel demand for pharmacovigilance services in the coming years.

Dearth of skilled healthcare professionals needed to analyse data and implement solutions can restrict market growth. Moreover, increased risk for data security that can be misused by the pharmacovigilance personnel can hamper business growth over the coming years.

Further key findings from the study suggest:

  • Phase IV held a dominant market share owing to the extensive post marketing surveillance of pharmaceuticals and increasing number of ADR incidences in the market
  • Phase III is anticipated to witness lucrative CAGR owing to increasing focus of pharmaceutical manufacturers on therapeutic development and safety monitoring
  • In service provider segment, contract outsourcing held a significant market share, owing to shift in focus of pharmaceutical companies to outsourcing services to reduce operational cost
  • Based on type of service, spontaneous reporting held the largest market share owing to its wide application in pharmacovigilance and benefits such as easy simulation of data sets for better drug comparison
  • Research organizations segment is anticipated to exhibit lucrative CAGR over the forecast period owing to increasing R&D for the development of novel biologics and medical devices
  • Asia Pacific pharmacovigilance market is anticipated to showcase lucrative CAGR in the forthcoming years
  • Industry participants are focusing on increasing R&D activities to develop better pharmacovigilance services.

The top players in this market are Clinquest Group B.V., Accenture, Plc, Cognizant Technology Solutions, iMED Global Corporation, Covance, Inc. ICON, Plc, inVentiv Health, Inc., Pharmaceutical Product Development LLC, Parexel International Corporation, PRA Health Sciences, Inc., F. Hoffmann-La Roche Ltd., Quintiles Transnational Holdings Inc, Sanofi , Wipro Limited, and Synowledge LLC, among others.

Request to Buy This Premium Report From here@ https://www.visionresearchreports.com/report/cart/28880

Segmentation:

Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2015 - 2026)

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2015 - 2026)

  • In-house
  • Contract Outsourcing

Pharmacovigilance Type of Methods Outlook (Revenue, USD Million, 2015 - 2026)

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance End Use Outlook (Revenue, USD Million, 2015 - 2026)

  • Hospitals
  • Research Organizations
  • Industrial

Pharmacovigilance Regional Outlook (Revenue, USD Million, 2015 - 2026)

  • North America
    • S.
    • Canada
  • Europe
    • K.
    • Germany
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • South Africa
    • Saudi Arabia

Request to Buy This Premium Report From here@ https://www.visionresearchreports.com/report/cart/28880

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews in North america
1.3.5.2 Data for primary interviews in Europe
1.3.5.3 Data for primary interviews in Asia Pacific
1.3.5.4 Data for primary interviews in Middle East and Africa
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Report Objectives
Chapter 2 Executive Summary
2.1 Market Outlook
2.1.1 Pharmacovigilance market Outlook, 2015 - 2026 (USD Million)
2.2 Segment Outlook
2.3 Competitive Outlook
2.4 Pharmacovigilance Market Summary, 2018
Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market analysis
3.1.2 Ancillary market Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Technology Timeline Overview
3.3.1 Technology Timeline Pharmacovigilance changing technology & adoption
3.4 Regulatory Framework
3.4.1 List of regulatory bodies
3.5 Pharmacovigilance Market Dynamics
3.5.1 Market driver analysis
3.5.1.1 Growing drug consumption and drug development rates
3.5.1.2 Increasing incidence of ADR and drug toxicity
3.5.1.3 Increasing trend of outsourcing pharmacovigilance services
3.5.2 Market restraint analysis
3.5.2.1 Lack of skilled labor
3.6 Pharmacovigilance Market Analysis Tools: Porters
3.6.1 Supplier Power
3.6.2 Buyer Power
3.6.3 Threat Of Substitutes
3.6.4 Threat Of New Entrants
3.6.5 Competitive Rivalary
3.7 PESTEL Analysis
3.7.1 Political Landscape
3.7.2 economic Landscape
3.7.3 technology Landscape
3.7.4 technology Landscape
3.7.5 social Landscape
3.8 Major Deals & Strategic Alliances Analysis
3.8.1 Mergers & Acquisitions
3.8.2 product launch
3.8.3 Expansion
3.8.4 Partnership & Collaborations
3.8.5 Market Entry Strategies
Chapter 4 Pharmacovigilance Market: Competitive Analysis
4.1 Market Participation Categorization
4.2 Public Companies
4.2.1 Company market position analysis
4.2.2 Competitive Dashboard Analysis
4.2.2.1 Market Differentiators
4.2.3 Company Market Share
4.2.4 Competitive Dashboard Analysis
4.3 Private Companies
4.3.1 List of key emerging companies
Chapter 5 Pharmacovigilance Market: Product Estimates & Trend Analysis
5.1 Product Market Share Analysis, 2018 & 2026
5.2 Product Dashboard
5.2.1 Preclinical
5.2.1.1 Preclinical market estimates and forecasts, 2015 - 2026 (USD Million)
5.2.2 Phase I
5.2.2.1 Phase I market estimates and forecasts, 2015 - 2026 (USD Million)
5.2.3 Phase II
5.2.3.1 Phase II market estimates and forecasts, 2015 - 2026 (USD Million)
5.2.4 Phase III
5.2.4.1 Phase III market estimates and forecasts, 2015 - 2026 (USD Million)
5.2.5 Phase IV
5.2.5.1 Phase IV market estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 6 Pharmacovigilance Market: Service provider Estimates & Trend Analysis
6.1 Service provider Market Share Analysis, 2018 & 2026
6.2 Service Provider Dashboard
6.3 In house
6.3.1 In house market estimates and forecasts, 2015 - 2026 (USD Million)
6.4 Contract outsourcing
6.4.1 Contract outsourcing market estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 7 Pharmacovigilance Market: Type Estimates & Trend Analysis
7.1 Type Market Share Analysis, 2018 & 2026
7.2 Type Dashboard
7.3 Spontaneous Reporting
7.3.1 Spontaneous Reporting market estimates and forecasts, 2015 - 2026 (USD Million)
7.4 Intensified ADR Reporting
7.4.1 Intensified ADR Reporting market estimates and forecasts, 2015 - 2026 (USD Million)
7.5 Targeted spontaneous reporting
7.5.1 Targeted spontaneous reporting market estimates and forecasts, 2015 - 2026 (USD Million)
7.6 Cohort Event Monitoring (CEM)
7.6.1 Cohort Event Monitoring (CEM) market estimates and forecasts, 2015 - 2026 (USD Million)
7.7 EHR Mining
7.7.1 EHR Mining market estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 8 Pharmacovigilance Market: End Use Estimates & Trend Analysis
8.1 End Use Market Share Analysis, 2018 & 2026
8.2 End Use Dashboard
8.3 Hospitals
8.3.1 Hospitals market estimates and forecasts, 2015 - 2026 (USD Million)
8.4 Research organizations
8.4.1 Research organizations market estimates and forecasts, 2015 - 2026 (USD Million)
8.5 Industrial
8.5.1 Industrial market estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 9 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, And End Use
9.1 Regional Market Snapshot
9.2 Market Share Analysis by Country, 2018
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 MEA
9.3 North America
9.3.1 North America Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.3.2 U.S.
9.3.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.3.3 Canada
9.3.3.1 Canada Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.4 Europe
9.4.1 Europe Pharmacovigilance MARKET estimates and forecasts, 2015 - 2026 (USD Million)
9.4.2 U.K.
9.4.2.1 U.K. Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.4.3 Germany
9.4.3.1 Germany Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.4.4 France
9.4.4.1 France Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.4.5 Italy
9.4.5.1 Italy Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.4.6 Russia
9.4.6.1 Russia Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.5 Asia Pacific
9.5.1 Asia Pacific Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.5.2 Japan
9.5.2.1 Japan Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.5.3 China
9.5.3.1 China Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.5.4 India
9.5.4.1 India Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.6 Latin America
9.6.1 Latin America Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.6.2 Mexico
9.6.2.1 Mexico Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.6.3 Brazil
9.6.3.1 Brazil Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.7 MEA
9.7.1 MEA Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.7.2 South Africa
9.7.2.1 South Africa Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
9.7.3 Saudi Arabia
9.7.3.1 Saudi Arabia Pharmacovigilance market estimates and forecasts, 2015 - 2026 (USD Million)
Chapter 10 Company Profiles
10.1 Accenture
10.1.1 Company overview
10.1.2 Financial performance
10.1.3 Product benchmarking
10.1.4 Strategic initiatives
10.2 Clinquest Group B.V.
10.2.1 Company overview
10.2.2 Product benchmarking
10.2.3 Strategic initiatives
10.3 Cognizant
10.3.1 Company overview
10.3.2 Financial Performance
10.3.3 Product benchmarking
10.3.4 Strategic initiatives
10.4 Laboratory Corporation of America Holdings
10.4.1 Company overview
10.4.2 Financial Performance
10.4.3 Product benchmarking
10.4.4 Strategic initiatives
10.5 IBM Corporation
10.5.1 Company overview
10.5.2 Product benchmarking
10.5.3 Strategic initiatives
10.6 ArisGlobal
10.6.1 Company overview
10.6.2 Financial Performance
10.6.3 Product benchmarking
10.6.4 Strategic initiatives
10.7 ICON Plc
10.7.1 Company overview
10.7.2 Product benchmarking
10.8 Capgemini
10.8.1 Company overview
10.8.2 Financial Performance
10.8.3 Product benchmarking
10.8.4 Strategic initiatives
10.9 iMEDGlobal
10.9.1 Company overview
10.9.2 Financial performance
10.9.3 Product benchmarking
10.9.4 Strategic initiatives
10.10 ITClinical
10.10.1 Company overview
10.10.2 Financial performance
10.10.3 Product benchmarking
10.10.4 Strategic initiatives
10.11 Foresight Group International AG
10.11.1 Company overview
10.11.2 Financial performance
10.11.3 Product benchmarking
10.11.4 Strategic initiatives
10.12 TAKE Solutions
10.12.1 Company overview
10.12.2 Financial performance
10.12.3 Product benchmarking
10.12.4 Strategic initiatives
10.13 PAREXEL International Corporation
10.13.1 Company overview
10.13.2 Financial performance
10.13.3 Product benchmarking
10.13.4 Strategic initiatives
10.14 BioClinica, Inc.
10.14.1 Company overview
10.14.2 Financial performance
10.14.3 Product benchmarking
10.14.4 Strategic initiatives
10.15 Wipro Limited
10.15.1 Company overview
10.15.2 Financial performance
10.15.3 Product benchmarking
10.15.4 Strategic initiatives
10.16 UNITED BIOSOURCE CORPORATION
10.16.1 Company overview
10.16.2 Financial performance
10.16.3 Product benchmarking
10.16.4 Strategic initiatives

List of Tables

TABLE 1 List of secondary sources
TABLE 2 List of key emerging companies
TABLE 3 North America Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 4 North America Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 5 North America Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 6 North America Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 7 U.S. Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 8 U.S. Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 9 U.S. Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 10 U.S. Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 11 Canada Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 12 Canada Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 13 Canada Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 14 Canada Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 15 Europe Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 16 Europe Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 17 Europe Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 18 Europe Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 19 U.K. Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 20 U.K. Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 21 U.K. Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 22 U.K. Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 23 Germany Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 24 Germany Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 25 Germany Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 26 France Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 27 France Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 28 France Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 29 France Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 30 Italy Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 31 Italy Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 32 Italy Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 33 Italy Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 34 Russia Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 35 Russia Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 36 Russia Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 37 Russia Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 38 Asia Pacific Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 39 Asia Pacific Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 40 Asia Pacific Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 41 Asia Pacific Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 42 Japan Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 43 Japan Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 44 Japan Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 45 Japan Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 46 China Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 47 China Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 48 China Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 49 China Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 50 India Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 51 India Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 52 India Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 53 India Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 54 Latin America Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 55 Latin America Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 56 Latin America Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 57 Latin America Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 58 Brazil Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 59 Brazil Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 60 Brazil Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 61 Brazil Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 62 Mexico Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 63 Mexico Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 64 Mexico Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 65 Mexico Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 66 MEA Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 67 MEA Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 68 MEA Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 69 MEA Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 70 South Africa Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 71 South Africa Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 72 South Africa Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 73 South Africa Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)
TABLE 74 Saudi Arabia Pharmacovigilance market estimates and forecasts, by product, 2015 - 2025 (USD Million)
TABLE 75 Saudi Arabia Pharmacovigilance market estimates and forecasts, by service provider, 2015 - 2025 (USD Million)
TABLE 76 Saudi Arabia Pharmacovigilance market estimates and forecasts, by type, 2015 - 2025 (USD Million)
TABLE 77 Saudi Arabia Pharmacovigilance market estimates and forecasts, by end use, 2015 - 2025 (USD Million)

List of Figures

Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Primary interviews in North America
Fig. 6 Primary interviews in Europe
Fig. 7 Primary interviews in Asia Pacific
Fig. 8 Primary interviews in Middle East and Africa
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Commodity flow analysis
Fig. 14 Pharmacovigilance market snapshot
Fig. 15 Penetration & growth prospect mapping
Fig. 16 Technology impact analysis
Fig. 17 Pharmacovigilance market dynamics
Fig. 18 Pharmacovigilance market driver impact
Fig. 19 Pharmacovigilance market restraint impact
Fig. 20 Strategy mapping
Fig. 21 Market participant categorization
Fig. 22 Company market position analysis
Fig. 23 Market differentiators
Fig. 24 Company market share analysis
Fig. 25 Competitive dashboard analysis
Fig. 26 Pharmacovigilance market: Product movement analysis
Fig. 27 Pharmacovigilance market product dashboard
Fig. 28 Global Preclinical market, 2015 - 2026 (USD Million)
Fig. 29 Global Phase I market, 2015 - 2026 (USD Million)
Fig. 30 Global Phase II market, 2015 - 2026 (USD Million)
Fig. 31 Global Phase III market, 2015 - 2026 (USD Million)
Fig. 32 Global Phase IV market, 2015 - 2026 (USD Million)
Fig. 33 Pharmacovigilance market: Service provider movement analysis
Fig. 34 Pharmacovigilance Service provider dashboard
Fig. 35 Global In house market, 2015 - 2026 (USD Million)
Fig. 36 Global Contract outsourcing market, 2015 - 2026 (USD Million)
Fig. 37 Pharmacovigilance market: Type movement analysis
Fig. 38 Pharmacovigilance Type dashboard
Fig. 39 Global Spontaneous Reporting market, 2015 - 2026 (USD Million)
Fig. 40 Global Intensified ADR Reporting market, 2015 - 2026 (USD Million)
Fig. 41 Global Targeted spontaneous reporting market, 2015 - 2026 (USD Million)
Fig. 42 Global Cohort Event Monitoring (CEM) market, 2015 - 2026 (USD Million)
Fig. 43 Global EHR Mining market, 2015 - 2026 (USD Million)
Fig. 44 Pharmacovigilance market: End Use movement analysis
Fig. 45 Pharmacovigilance End Use dashboard
Fig. 46 Global Hospitals market, 2015 - 2026 (USD Million)
Fig. 47 Global Research organizations market, 2015 - 2026 (USD Million)
Fig. 48 Regional market place: Key takeaways
Fig. 49 North America Pharmacovigilance market share by countries, 2018
Fig. 50 Europe Pharmacovigilance market share by countries, 2018
Fig. 51 Asia Pacific Pharmacovigilance market share by countries, 2018
Fig. 52 Latin America Pharmacovigilance market share by countries, 2018
Fig. 53 MEA Pharmacovigilance market share by countries, 2018
Fig. 54 Regional outlook, 2018 & 2026
Fig. 55 North America Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 56 U.S. Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 57 Canada Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 58 Europe Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 59 U.K. Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 60 Germany Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 61 France Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 62 Italy Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 63 Russia Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 64 Asia Pacific Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 65 Japan Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 66 China Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 67 India Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 68 Latin America Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 69 Mexico Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 70 Brazil Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 71 MEA Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 72 South Africa Pharmacovigilance market, 2015 - 2026 (USD Million)
Fig. 73 Saudi Arabia Pharmacovigilance market, 2015 - 2026 (USD Million)

Request to Buy This Premium Report From here@ https://www.visionresearchreports.com/report/cart/28880